Strategic Partner
Dr. GPCR x GeneTex : A Challenge to the GPCR Community
GPCR antibody reliability has been a bottleneck for years. GeneTex is building an extensive recombinant monoclonal GPCR antibody portfolio, and Dr. GPCR provides the community platform to challenge, validate, and pressure-test performance in real labs.
That's why GeneTex is offering free antibody samples to GPCR researchers — not as a promotion, but as a challenge.
-
Near-comprehensive coverage of human nonsensory and orphan GPCR targets
-
Structured validation with KO/KD, endogenous expression, and orthogonal approaches
-
Free samples available — we want your feedback, positive or negative, because that's how trust is built
GeneTex Is Tackling the GPCR Antibody Problem Head On
The GPCR field has long struggled with unreliable antibodies — inconsistent, poorly validated, and hard to reproduce. GeneTex is changing that with three commitments built into every product:
-
Recombinant production eliminates lot-to-lot variation and stock shortages permanently
-
Five-Pillar validation promotes structured, multi-evidence characterization above industry norms
-
Complete validation data shared openly before purchase — no black boxes, full transparency
We want to interact with GPCR scientists to challenge our antibodies in their own labs. Our hope is to strengthen our GPCR antibody catalog through rigorous "field testing" in laboratories with expert knowledge and specialized reagents. GeneTex believes this is the only way a new antibody can earn the trust of the GPCR research community.
— GeneTex, on partnering with Dr. GPCR Ecosystem
How GeneTex Generates & Validates GPCR Antibodies
Based on the approach described in Starkie et al. (2016), combining multi-parameter FACS-based memory B cell selection with recombinant cloning and multi-layered Five-Pillar validation.
1.
Memory B Cell Selection
Multi-parameter FACS identifies antigen-specific IgG+ memory B cells from immunized rabbits or mice. Clones are assayed during cell expansion to rapidly identify high-performers with application-relevant activity.
2.
Recombinant IgG Production
Matched heavy and light chains are cloned and expressed as recombinant monoclonals. Peptide immunogens from GPCR extracellular or intracellular domains are carefully vetted to avoid cross-reactivity.
3.
Five-Pillar Validation
Every antibody is characterized using at least one, and preferably more, of the Five Pillars (Uhlen et al., 2016). Human GPCR arrays are employed when feasible for additional cross-reactivity screening.
Antibody validation incorporates a ”Five-Pillar” framework with optimized experimental strategies to make the strongest case for GPCR antibody clone target specificity. KO/KD testing is prioritized.
These strategies are summarized below:
I. Knockout / Knockdown Lysates
KO/KD cell lines and lysates confirm true target specificity — the gold standard for antibody validation that eliminates non-specific binding artifacts.
II. Comparable Antibodies
GeneTex antibodies are benchmarked directly against other high-quality, well-published antibodies for transparent, side-by-side performance comparison.
III. Cell Fractionation
Fractionation experiments confirm expected subcellular localization patterns, adding spatial context to target specificity evidence.
IV. Endogenous Expression Detection
Antibodies are validated for detection of native GPCR expression in biologically relevant cell and tissue contexts without over-expression systems.
V. Over-expression Validation
Over-expression systems confirm antibody reactivity and characterize performance across a wide range of receptor expression levels.
+ Human GPCR Arrays
Specialized testing using human GPCR arrays assesses cross-reactivity across the full GPCR superfamily when feasible — providing uniquely comprehensive specificity data.
Validation Case Studies
The following antibodies represent examples of GeneTex's GPCR validation approach in action. Each one was characterized across multiple assays, cell lines, and tissues — including endogenous and overexpressed systems — to build the strongest possible case for specificity and reliability.
Case Study : GPRC5A antibody [HL1864] — GTX637589
A rabbit recombinant monoclonal antibody raised against the intracellular domain of human GPRC5A (RAI3). Validated for Western Blot, ICC/IF, and IHC-P, with knockout cell line confirmation and head-to-head comparison against a highly cited competitor. Highly recommended for IHC-P in human tissues.
Case Study : CXCR2 antibody [HL2604] — GTX639056
A rabbit recombinant monoclonal antibody targeting the extracellular domain of human CXCR2. Validated across Western Blot, ICC/IF, Flow Cytometry, and Functional Assay, with cell fractionation, GPCR array specificity testing, and competitor benchmarking. Suitable for both modified and unmodified cell systems.
Case Study : GABA B Receptor 2 antibody [HL4551] — GTX644219
A rabbit recombinant monoclonal antibody raised against the intracellular domain of human GABA B Receptor 2, with cross-reactivity to mouse and rat. Validated for Western Blot, IHC-P, and fluorescent IHC (IHC-Fr), with RNA expression correlation across multiple tissues. Highly recommended for IHC-P in mouse and rat tissues.
Case Study : Dopamine Receptor D2 antibody [HL1478] — GTX636952
A rabbit recombinant monoclonal antibody targeting the extracellular domain of human Dopamine Receptor D2, with cross-reactivity to mouse and rat. Validated for Western Blot, ICC/IF, Flow Cytometry, and Functional Assay, including GPCR array specificity screening and direct comparison against a competitor antibody in human brain and mouse tissue.
About GeneTex
GeneTex is a multinational antibody manufacturer founded in San Antonio, Texas in 1997. Since then, it has grown into a global leader in antibody science with a catalog spanning nearly all fields of biomedical research — from cancer biology and neuroscience to infectious disease, metabolism, and immunology.
In 2020, GeneTex launched new facilities for recombinant monoclonal antibody and protein production, paired with enhanced "Five-Pillar" validation protocols with a strong emphasis on knockout/knockdown (KO/KD) testing. In 2025, a new office opened in Germany to better serve European researchers.
Their primary initiative for the GPCR community: a near-comprehensive catalog of recombinant monoclonal antibodies targeting the ~360 human nonsensory and orphan GPCR receptors — the most diverse, expansive, and meticulously verified antibody portfolio for GPCR biology research ever assembled.